AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.

05/02/2026, 4:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.

04/30/2026, 12:00 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role

A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquestive's stock price plummeted 37% from $6.21 to $3.91 per share. Investors who purchased shares between June 16, 2025 and January 8, 2026 have until May 4, 2026 to apply as lead plaintiff.

04/29/2026, 8:04 PM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.

04/28/2026, 9:00 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements about the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.

04/27/2026, 12:00 PM • GlobeNewswire

AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm is encouraging investors who suffered losses in securities class action lawsuits against Aquestive Therapeutics, Babcock & Wilcox Enterprises, and Snowflake Inc. to secure legal counsel before upcoming deadlines. The firm is seeking lead plaintiffs for cases involving alleged false statements and disclosure failures.

04/25/2026, 10:29 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.

04/23/2026, 12:00 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

Pomerantz Law Firm has filed class action lawsuits against Aquestive Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics, alleging securities fraud and unlawful business practices. The lawsuit against Aquestive was triggered by an FDA letter identifying deficiencies in the Anaphylm NDA review, causing the stock to drop 37% on January 9, 2026. Investors have until May 4, 2026, to request Lead Plaintiff status.

04/21/2026, 3:59 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSE

Pomerantz Law Firm has filed class action lawsuits against Eos Energy Enterprises, Nektar Therapeutics, and Aquestive Therapeutics for alleged securities fraud. Eos Energy's stock fell 39.44% after missing earnings estimates significantly, with the company citing production issues and quality control problems.

04/21/2026, 3:59 PM • GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

Rosen Law Firm is reminding investors who purchased Aquestive Therapeutics securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.

04/19/2026, 1:07 PM • GlobeNewswire

AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

Aquestive Therapeutics faces a securities class action lawsuit covering the period June 16, 2025 to January 8, 2026. The company allegedly made false statements about its Anaphylm drug application while concealing material facts about human factors in the sublingual film's use. On January 9, 2026, the FDA identified deficiencies that delayed approval, causing the stock to plummet 37% in a single day from $6.21 to $3.91 per share.

04/17/2026, 9:00 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and certain officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product that could impact regulatory approval.

04/16/2026, 12:00 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role

A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 deadline, resulting in a 37% stock price decline on January 9, 2026. Investors have until May 4, 2026 to apply as lead plaintiff.

04/13/2026, 6:45 PM • GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

Rosen Law Firm is notifying investors in Aquestive Therapeutics, Franklin BSP Realty Trust, and ImmunityBio about ongoing securities class action lawsuits. Investors who purchased securities during specified class periods are encouraged to secure legal counsel before important deadlines. The lawsuits allege false or misleading statements regarding product applications and disclosures.

04/10/2026, 6:48 PM • GlobeNewswire

FBRT DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRT

Rosen Law Firm has filed securities class action lawsuits against Franklin BSP Realty Trust (FBRT) and other companies, alleging that defendants made false and misleading statements about business prospects and dividend sustainability during the Class Period. Investors with losses exceeding $100,000 are encouraged to join the class action before the April 27, 2026 lead plaintiff deadline.

04/10/2026, 6:31 PM • GlobeNewswire